OBJECTIVE: Glutaminase 1 (Gls1) is the first enzyme in glutaminolysis. The selective Gls1 inhibitor bis-2-(5-phenylacetamido-1,3,4-thiadiazol-2-yl)ethyl sulfide (BPTES) suppresses Th17 development and ameliorates experimental autoimmune encephalomyelitis (EAE). The present study was undertaken to investigate whether inhibition of glutaminolysis is beneficial for the treatment of systemic lupus erythematosus (SLE), and the involved mechanisms. METHODS: MRL/lpr mice were treated with BPTES or vehicle control, and disease activity was examined. Then naive CD4+ T cells from patients with SLE were cultured under Th17-polarizing conditions with BPTES or vehicle. Furthermore, using newly generated Gls1 conditional-knockout mice, in vitro Th17 differentiation was examined, and EAE was induced in the mice. Glutaminolysis and glycolysis were measured with an extracellular flux analyzer. The expression of hypoxia-inducible factor 1α (HIF-1α) was examined by Western blotting. RESULTS: Treatment of MRL/lpr mice with BPTES improved autoimmune pathology in a Th17-dependent manner. T cells from patients with SLE treated with BPTES displayed decreased Th17 differentiation (P < 0.05). Using the conditional-knockout mice, we demonstrated that both in vitro Th17 differentiation (P < 0.05) and the development of EAE were dependent on Gls1. Gls1 inhibition reduced glycolysis and the expression of HIF-1α protein, which induces glycolysis. CONCLUSION: We demonstrated that inhibition of glutaminolysis represents a potential new treatment strategy for patients with SLE and Th17-related autoimmune diseases. Mechanistically, we have shown that inhibition of glutaminolysis affects the glycolysis pathway by reducing HIF-1α protein in Th17 cells.
OBJECTIVE:Glutaminase 1 (Gls1) is the first enzyme in glutaminolysis. The selective Gls1 inhibitor bis-2-(5-phenylacetamido-1,3,4-thiadiazol-2-yl)ethyl sulfide (BPTES) suppresses Th17 development and ameliorates experimental autoimmune encephalomyelitis (EAE). The present study was undertaken to investigate whether inhibition of glutaminolysis is beneficial for the treatment of systemic lupus erythematosus (SLE), and the involved mechanisms. METHODS: MRL/lprmice were treated with BPTES or vehicle control, and disease activity was examined. Then naive CD4+ T cells from patients with SLE were cultured under Th17-polarizing conditions with BPTES or vehicle. Furthermore, using newly generated Gls1 conditional-knockout mice, in vitro Th17 differentiation was examined, and EAE was induced in the mice. Glutaminolysis and glycolysis were measured with an extracellular flux analyzer. The expression of hypoxia-inducible factor 1α (HIF-1α) was examined by Western blotting. RESULTS: Treatment of MRL/lprmice with BPTES improved autoimmune pathology in a Th17-dependent manner. T cells from patients with SLE treated with BPTES displayed decreased Th17 differentiation (P < 0.05). Using the conditional-knockout mice, we demonstrated that both in vitro Th17 differentiation (P < 0.05) and the development of EAE were dependent on Gls1. Gls1 inhibition reduced glycolysis and the expression of HIF-1α protein, which induces glycolysis. CONCLUSION: We demonstrated that inhibition of glutaminolysis represents a potential new treatment strategy for patients with SLE and Th17-related autoimmune diseases. Mechanistically, we have shown that inhibition of glutaminolysis affects the glycolysis pathway by reducing HIF-1α protein in Th17 cells.
Authors: Tao Xu; Kelly M Stewart; Xiaohu Wang; Kai Liu; Min Xie; Jae Kyu Ryu; Ke Li; Tianhua Ma; Haixia Wang; Lu Ni; Saiyong Zhu; Nan Cao; Dongwei Zhu; Yu Zhang; Katerina Akassoglou; Chen Dong; Edward M Driggers; Sheng Ding Journal: Nature Date: 2017-08-02 Impact factor: 49.962
Authors: Michihito Kono; Nobuya Yoshida; Kayaho Maeda; Nicole E Skinner; Wenliang Pan; Vasileios C Kyttaris; Maria G Tsokos; George C Tsokos Journal: Proc Natl Acad Sci U S A Date: 2018-08-27 Impact factor: 11.205
Authors: Amira Elgogary; Qingguo Xu; Brad Poore; Jesse Alt; Sarah C Zimmermann; Liang Zhao; Jie Fu; Baiwei Chen; Shiyu Xia; Yanfei Liu; Marc Neisser; Christopher Nguyen; Ramon Lee; Joshua K Park; Juvenal Reyes; Thomas Hartung; Camilo Rojas; Rana Rais; Takashi Tsukamoto; Gregg L Semenza; Justin Hanes; Barbara S Slusher; Anne Le Journal: Proc Natl Acad Sci U S A Date: 2016-08-24 Impact factor: 11.205
Authors: Eric V Dang; Joseph Barbi; Huang-Yu Yang; Dilini Jinasena; Hong Yu; Ying Zheng; Zachary Bordman; Juan Fu; Young Kim; Hung-Rong Yen; Weibo Luo; Karen Zeller; Larissa Shimoda; Suzanne L Topalian; Gregg L Semenza; Chi V Dang; Drew M Pardoll; Fan Pan Journal: Cell Date: 2011-08-25 Impact factor: 41.582
Authors: Michihito Kono; Kayaho Maeda; Irina Stocton-Gavanescu; Wenliang Pan; Masataka Umeda; Eri Katsuyama; Catalina Burbano; Seo Yeon K Orite; Milena Vukelic; Maria G Tsokos; Nobuya Yoshida; George C Tsokos Journal: JCI Insight Date: 2019-06-20
Authors: Yiming Yin; Seung-Chul Choi; Zhiwei Xu; Daniel J Perry; Howard Seay; Byron P Croker; Eric S Sobel; Todd M Brusko; Laurence Morel Journal: Sci Transl Med Date: 2015-02-11 Impact factor: 17.956
Authors: Diana C Contreras Healey; Jacqueline Y Cephus; Sierra M Barone; Nowrin U Chowdhury; Debolanle O Dahunsi; Matthew Z Madden; Xiang Ye; Xuemei Yu; Kellen Olszewski; Kirsten Young; Valerie A Gerriets; Peter J Siska; Ryszard Dworski; Jonathan Hemler; Jason W Locasale; Masha V Poyurovsky; R Stokes Peebles; Jonathan M Irish; Dawn C Newcomb; Jeffrey C Rathmell Journal: J Immunol Date: 2021-02-08 Impact factor: 5.422
Authors: Brian J Andonian; Andrew Johannemann; Monica J Hubal; David M Pober; Alec Koss; William E Kraus; David B Bartlett; Kim M Huffman Journal: Arthritis Res Ther Date: 2021-07-10 Impact factor: 5.156